Table 3.

Univariate and multivariate analysis for achievement of CR at R1 evaluation

	CR/N (%)	Univariate		Multivariate*
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Age, y
<60	77/95 (81.1)	3.45 (1.65-7.20)	.001	2.55 (0.99-6.57)	.05	2.37 (0.82-6.88)	.11
≥60	31/56 (55.4)	1.00		1.00		1.00
Sex
Male	53/78 (67.9)	1.00		1.00		1.00
Female	55/73 (75.3)	1.44 (0.71-2.94)	.32	1.33 (0.54-3.27)	.53	1.07 (0.40-2.82)	.89
WBCs, ×109/L
≤50	75/108 (69.4)	1.00				1.00
>50	33/43 (76.7)	1.45 (0.64-3.29)	.37			1.18 (0.40-3.51)	.77
AML
Secondary	4/11 (36.4)	1.00				1.00
De novo	104/140 (74.3)	5.06 (1.40-18.29)	.01			3.25 (0.61-17.22)	.17
ECOG performance status
0	62/77 (80.5)	3.44 (0.93-12.82)	.07	1.61 (0.33-7.81)	.55	1.77 (0.33-9.65)	.51
1	40/63 (63.5)	1.45 (0.40-5.28)	.57	1.20 (0.25-5.69)	.82	1.25 (0.23-6.71)	.79
2	6/11 (54.5)	1.00		1.00		1.00
NILG risk class
SR	46/51 (90.2)	5.64 (2.06-15.44)	.0008	3.64 (1.17-11.35)	.02
HR	62/100 (62.0)	1.00		1.00
ELN 2010 risk class†
Favorable	51/56 (91.1)	12.11 (3.90-37.65)	<.0001			5.90 (1.57-22.18)	.008
Intermediate 1	24/35 (68.6)	2.59 (0.98-6.87)	.05			1.41 (0.40-4.90)	.59
Intermediate 2	11/18 (61.1)	1.87 (0.59-5.94)	.29			1.03 (0.25-4.26)	.97
Adverse	16/35 (45.7)	1.00				1.00
Treatment
ICE	50/82 (61.0)	1.00		1.00		1.00
sHD	58/69 (84.1)	3.38 (1.54-7.38)	.002	2.27 (0.90-5.71)	.08	2.38 (0.84-6.71)	.10
PBC
<1.5	24/55 (43.6)	1.00		1.00		1.00
≥1.5	84/96 (87.5)	9.04 (4.04-20.24)	<.0001	7.01 (2.91-16.91)	<.0001	5.87 (2.22-15.53)	.0004

OR, odds ratio.

^*Two multivariate models including different risk classifications (model with NILG risk excludes factors already considered in the risk construction).

^†Evaluable patients = 144.